Printer Friendly

CELL ANALYSIS SYSTEMS JOINS BECTON DICKINSON

 CELL ANALYSIS SYSTEMS JOINS BECTON DICKINSON
 ELMHURST, Ill., March 19 /PRNewswire/ -- Becton Dickinson and


Company (NYSE: BDX) has announced the acquisition of Cell Analysis Systems, Inc. (CAS), a company that manufactures computerized image analysis equipment and related reagents for research use by pathology laboratories involved in the diagnosis and prognosis of cancer. Becton Dickinson has been an investor in the company since 1987.
 BDCAS is the latest addition to a family of businesses developed at Becton Dickinson dedicated to research, diagnosis and improved patient management in the area of AIDS, other immunological diseases and cancer. These include Becton Dickinson Image Cytometry Systems in Leiden, Holland and Becton Dickinson Immunocytometry Systems in San Jose, Calif.
 BDCAS, located in Elmhurst, was founded in 1982 by James W. Bacus, Phd., an acknowledged pioneer in the field of computerized imaging diagnostics. BDCAS now becomes a division of Becton Dickinson with Dr. Bacus as division president.
 "It is a pleasure to welcome CAS to BD. We admire the caliber of its people and the quality of its products," said Walter Miller, president of the diagnostic sector. "CAS's expertise and proprietary technology complement our existing cellular analysis business and strengthen our overall market position and potential for future growth in this developing field."
 Image Analysis: Automating the Microscope.
 For years, pathologists have used microscopes to visually examine cellular morphology in tissue and cell preparations, but analysis has been subjective and is dependent on the observer's ability to interpret the images. Thus, it has been difficult to standardize interpretation from one person to another. With image analysis, subjectivity of interpretation is reduced as images can be quantified making standardization from lab to lab possible. Image analysis converts the microscope image to a digital image which can be enhanced and analyzed using image processing and computer technologies. This information is then recorded and displayed allowing statistical characterization of the cells analyzed.
 The BDCAS image analysis workstation allows pathologists to visually inspect cells while augmenting the analysis with computerized image processing and advanced slide staining techniques, including monoclonal antibody technology. The company has 13 issued patents covering this technology. The BDCAS image workstation includes software and reagents for specific applications, and research assays for the prognosis and treatment of various cancers.
 The BDCAS breast cancer panel of tests is being evaluated for usage in choosing breast cancer treatment options; it may be especially helpful in determining the course of treatment for women with lymph node negative breast cancers. BDCAS assays for prostate cancer are being evaluated for use in conjunction with new ultrasound guided, microscopic, prostate tissue sampling techniques to evaluate the possibility of containment, or spread, of prostate cancer.
 Becton Dickinson a Pioneer in Advanced Cell Analysis.
 Becton Dickinson pioneered the development of advanced cell analysis technology in the 1970s with the development of the first commercially available Fluorescence Activated Cell Sorter (FACS) and the creation of the Becton Dickinson Monoclonal Center, Inc., for research in immunology and development of monoclonal antibody reagents for use in flow cytometry. Becton Dickinson Immunocytometry Systems (BDIS) was formed in 1984 from the merger of these two groups and is today the worldwide leader in flow cytometry for research and clinical applications. This technology has been instrumental in unraveling the complexities of the immune system and has led to major advances in the understanding of AIDS and leukemia. Today FACS brand flow cytometers are used worldwide to facilitate the diagnosis, monitoring and staging of immunological diseases such as AIDS, leukemia and other cancers.
 In 1990, Becton Dickinson Image Cytometry Systems (BDIC) was formed in Leiden, The Netherlands, after acquiring technology from Wild-Leitz and Professor J.S. Ploem at the University of Leiden. Leiden has been a center for developments in microscopy since the 17th century when Anton van Leeuwenhoek invented the first microscope. Based on acquired technology, BDIC has developed an automated rare event image cytometer. This sophisticated system is designed to rapidly screen slides too find abnormal cells that may be present in very small numbers. This system will be used for research in pathology and oncology to improve detection and monitoring of abnormal cells. Earlier detection of disease is likely to lead to more effective therapies in the treatment of disease.
 Becton Dickinson is a global medical technology company focused on disposable medical devices and diagnostic systems. Its sales, exceeding $2 billion annually, rank the company among the largest in the health care industry. Becton Dickinson employs more than 18,000 people worldwide, with more than 60 manufacturing and research facilities located in 15 nations in North America, Latin America, the Caribbean, Europe and the Far East.
 -0- 3/19/92
 /CONTACT: James W. Bacus of Becton Dickinson, 708-833-1717/
 (BDX) CO: Becton Dickinson and Company; Cell Analysis Systems, Inc. ST: New Jersey, Illinois IN: MTC SU: TNM


SH-TQ -- NY068 -- 9812 03/19/92 15:57 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1992
Words:806
Previous Article:FLEMING TO SUPPLY ALBERTSON'S IN FLORIDA
Next Article:SOLECTRON CORP. ANNOUNCES TWO FOR ONE STOCK SPLIT
Topics:


Related Articles
BECTON DICKINSON IMMUNOCYTOMETRY SYSTEMS FILES 510(K) FOR FDA CLEARANCE OF FACSCOUNT, A COMPLETE SYSTEM FOR MONITORING PATIENTS WITH HIV INFECTION;...
BECTON DICKINSON NAMES ROSEMARY MEDE VICE PRESIDENT, HUMAN RESOURCES
BECTON DICKINSON CELLULAR IMAGING SYSTEMS NAMES W.H. WAN PRESIDENT OF NEW DIVISION
BECTON DICKINSON IMMUNOCYTOMETRY SYSTEMS NAMES NEW PRESIDENT
ICN PHARMACEUTICALS ACQUIRES DIVISION OF BECTON DICKINSON
BECTON DICKINSON NAMES PRESIDENT TO NEW INTEGRATED SALES ORGANIZATION
Baxter: Federal Jury Awards $2.3 Million to Johns Hopkins, Baxter and Becton Dickinson in Patent Infringement Case
Becton Dickinson Acquires MedPlus' IntelliCode Division For $17.4 Million And Makes Investment Of $2 Million In Common Stock
Luther Medical Products, Inc. To Be Acquired By Becton Dickinson.
Luther Medical Products Announces Increase in Merger Consideration To $4.70 Per Share and License Option Agreement with Becton Dickinson.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters